As a number of cancers overexpress both HER2 and EGFR (i.e. gastric, ovarian, breast), our results have potential to be translated into a wide range of solid tumors and PET imaging has potential to be used to identify which patients would be susceptible to dual HER2/EGFR combination therapies. The gene discussed is ERBB2; the disease is cancer.